ClinicalTrials.gg

Program

elisrasib

Its studies are led by D3 Bio (Wuxi).

Furthest: phase 2, since May 25, 20222 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
D3 Bio (Wuxi)21 open or runningphase 2since May 25, 2022May 25, 2022Apr 2027phase 2 · NCT05410145

Also a collaborator on its studies: Fortrea.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 25, 2022First study: phase 2 study in KRAS P.G12CFirst studyNCT05410145 · 442 planned · United States, Australia, China and more
  2. Jul 10, 2025Phase 1 study in Healthy Adult VolunteersNCT07093398 · 26 enrolled · Australia

Ahead

  1. Apr 2027Primary completion: phase 2 study in KRAS P.G12CNCT05410145

TargetBeta

KRAS →read by rule
“An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07093398Healthy Adult Volunteers · Australia1CompletedNov 12, 202526
NCT05410145KRAS P.G12C · United States, Australia, China and more2RecruitingApr 2027442

How it is read

Names in the registry

  • “D3S-001”, 2 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.